Understanding the multifaceted role of inflammatory mediators in ischemic stroke

Current Medicinal Chemistry

Volumn 21, Issue 18, 2014, Pages 2098-2117

  Amantea, D ^a   Tassorelli, C ^b   Petrelli, F ^a,c   Certo, M ^a   Bezzi, P ^c   Micieli, G ^b   Corasaniti, M T ^d   Bagetta, G ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Brain ischemia; Cytokines; Immune system; Ischemic stroke; Neuroinflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE; CYTOKINE; ENZYME;

ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; DENDRITIC CELL; GLIA CELL; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MICROGLIA; NEUTROPHIL; REGENERATION; REVIEW; SIGNAL TRANSDUCTION; SPATIOTEMPORAL ANALYSIS; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; STROKE; T-LYMPHOCYTES;

EID: 84899830705     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131227162634     Document Type: Review

References (400)

1. Wittchen, H.U.; Jacobi, F.; Rehm, J.; Gustavsson, A.; Svensson, M.; Jönsson, B.; Olesen, J.; Allgulander, C.; Alonso, J.; Faravelli, C.; Fratiglioni, L.; Jennum, P.; Lieb, R.; Maercker, A.; van Os, J.; Preisig, M.; Salvador-Carulla, L.; Simon, R.; Steinhausen, H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol., 2011, 21, 655-679.
2. Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Huffman, M.D.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Magid, D.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; McGuire, D.K.; Mohler, E.R.; Moy, C.S.; Mussolino, M.E.; Nichol, G.; Paynter, N.P.; Schreiner, P.J.; Sorlie, P.D.; Stein, J.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2013 Update: A Report From the American Heart Association. Circulation, 2013, 127, 143-152.
3. Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Dávalos, A.; Guidetti, D.; Larrue, V.; Lees, K.R.; Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med., 2008, 359, 1317-1329.
4. Huang, P.; Chen, C.H.; Yang, Y.H.; Lin, R.T.; Lin, F.C.; Liu, C.K. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc. Dis., 2006, 22, 423-428.
5. Ginsberg, M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology, 2008, 55, 363-389.
6. Moskowitz, M.A.; Lo, E.H.; Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron, 2010, 67, 181-198.
7. Amantea, D.; Nappi, G.; Bernardi, G.; Bagetta, G.; Corasaniti, M.T. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J., 2009, 276, 13-26.
8. Iadecola, C.; Anrather, J. The immunology of stroke: from mechanisms to translation. Nat. Med., 2011, 17, 796-808.
9. Sherman, D.G. The Enlimomab Acute Stroke Trial: final results (abstract and presentation) in 49th Annual Meeting of the American Academy of Neurology. Neurology, 1997, 48, A270.
10. Furuya, K.; Takeda, H.; Azhar, S.; McCarron, R.M.; Chen, Y.; Ruetzler, C.A.; Wolcott, K.M.; DeGraba, T.J.; Rothlein, R.; Hugli, T.E.; del Zoppo, G.J.; Hallenbeck, J.M. Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke, 2001, 32, 2665-2674.
11. Whiteley, W.; Jackson, C.; Lewis, S.; Lowe, G.; Rumley, A.; Sandercock, P.; Wardlaw, J.; Dennis, M.; Sudlow, C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med., 2009, 6(9), e1000145.
12. Tang, Y.; Xu, H.; Du, X.; Lit, L.; Walker, W.; Lu, A.; Ran, R.; Gregg, J.P.; Reilly, M.; Pancioli, A.; Khoury, J.C.; Sauerbeck, L.R.; Carrozzella, J.A.; Spilker, J.; Clark, J.; Wagner, K.R.; Jauch, E.C.; Chang, D.J.; Verro, P.; Broderick, J.P.; Sharp, F.R. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab., 2006, 26, 1089-1102.
13. Barr, T.L.; Conley, Y.; Ding, J.; Dillman, A.; Warach, S.; Singleton, A.; Matarin, M. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology, 2010, 75, 1009-1014.
14. Oh, S.H.; Kim, O.J.; Shin, D.A.; Song, J.; Yoo, H.; Kim, Y.K.; Kim, J.K. Alteration of immunologic responses on peripheral blood in the acute phase of ischemic stroke: blood genomic profiling study. J. Neuroimmunol., 2012, 249, 60-65.
15. Akopov, S.E.; Simonian, N.A.; Grigorian, G.S. Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage. Stroke, 1996, 27, 1739-1743.
16. Fassbender, K.; Rossol, S.; Kammer, T.; Daffertshofer, M.; Wirth, S.; Dollman, M.; Hennerici, M. Proinflammatory cytokines in serum of patients with acute cerebral damage and outcome of disease. J. Neurol. Sci., 1994, 122, 135-139.
17. Smith, C.J.; Emsley, H.C.A.; Gavin, C.M.; Georgiou, R.F.; Vail, A.; Barberan, E.M.; Zoppo, G.J.; Hallenbeck, J.M.; Rothwell, N.J.; Hopkins, S.J.; Tyrrell, P.J. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischemic stroke correlate with brain infarct volume, stroke severity and longterm outcome. BMC Neurol., 2004, 4, 2.
18. Basic Kes, V.; Simundic, A.M.; Nikolac, N.; Topic, E.; Demarin, V. Pro-inflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin. Biochem., 2008, 41, 1330-1334.
19. Chang, L.T.; Yuen, C.M.; Liou, C.W.; Lu, C.H.; Chang, W.N.; Youssef, A.A.; Yip, H.K. Link between interleukin-10 level and outcome after ischemic stroke. Neuroimmunomodulation, 2010, 17, 223-228.
20. del Zoppo, G.J. Acute anti-inflammatory approaches to ischemic stroke. Ann. N. Y. Acad. Sci., 2010, 1207, 143-148.
21. Meisel, C., Schwab, J., Prass, K., Meisel, A.; Dirnagl, U. Central nervous system injury-induced immune deficiency syndrome. Nat. Rev. Neurosci., 2005, 6, 775-786.
22. Dirnagl, U.; Klehmet, J.; Braun, J.S.; Harms, H.; Meisel, C.; Ziemssen, T.; Prass, K.; Meisel, A. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke, 2007, 38, 770-773.
23. Haeusler, K.G.; Schmidt, W.U.; Föhring, F.; Meisel, C.; Helms, T.; Jungehulsing, G.J.; Nolte, C.H.; Schmolke, K.; Wegner, B.; Meisel, A.; Dirnagl, U.; Villringer, A.; Volk, H.D. Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc. Dis., 2008, 25, 50-58.
24. Prass, K.; Braun, J.S.; Dirnagl, U.; Meisel, C.; Meisel, A. Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke, 2006, 37, 2607-2612.
25. del Zoppo, G.J. The neurovascular unit, matrix proteases, and innate inflammation. Ann. N. Y. Acad. Sci., 2010, 1207, 46-49.
26. Atkinson, C.; Zhu, H.; Qiao, F.; Varela, J.C.; Yu, J.; Song, H.; Kindy, M.S.; Tomlinson, S. Complement-dependent P-selectin expression and injury following ischemic stroke. J. Immunol., 2006, 177, 7266-7274.
27. Nieswandt, B.; Pleines, I.; Bender, M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J. Thromb. Haemost., 2011, 1, 92-104.
28. Brennan, F.H.; Anderson, A.J.; Taylor, S.M.; Woodruff, T.M.; Ruitenberg, M.J. Complement activation in the injured central nervous system: another dual-edged sword? J. Neuroinflammation, 2012, 9, 137.
29. Orsini, F.; Villa, P.; Parrella, S.; Zangari, R.; Zanier, E.R.; Gesuete, R.; Stravalaci, M.; Fumagalli, S.; Ottria, R.; Reina, J.J.; Paladini, A.; Micotti, E.; Ribeiro-Viana, R.; Rojo, J.; Pavlov, V.I.; Stahl, G.L.; Bernardi, A.; Gobbi, M.; De Simoni, M.G. Targeting mannose- binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation, 2012, 126, 1484-1494.
30. Bevilacqua, M.P.; Stengelin, S.; Gembrone, M.A. Jr.; Seed, B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 1989, 243, 1162-1165.
31. Granger, D.N.; Benoit, J.N.; Suzuki, M.; Grisham, M.B. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am. J. Physiol., 1989, 257, G683-G688.
32. McEver, R.P. Selectins: Novel receptors that mediate leukocyte adhesion during inflammation. Thromb. Haemost., 1991, 65, 223-228.
33. Mori, E.; del Zoppo, G.J.; Chambers, J.D.; Copeland, B.R.; Arfors, K.E. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke, 1992, 23, 712-718.
34. Wong, C.H.; Crack, P.J. Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemiareperfusion injury. Curr. Med. Chem., 2008, 15, 1-14.
35. Yilmaz, G.; Granger, D.N. Leukocyte recruitment and ischemic brain injury. Neuromol. Med., 2010, 12, 193-204.
36. Atochin, D.N.; Wang, A.; Liu, V.W.; Critchlow, J.D.; Dantas, A.P.; Looft-Wilson, R.; Murata, T.; Salomone, S.; Shin, H.K.; Ayata, C.; Moskowitz, M.A.; Michel, T.; Sessa, W.C.; Huang, P.L. The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo. J. Clin. Invest., 2007, 117, 1961-1967.
37. Ishikawa, M.; Zhang, J.H.; Nanda, A.; Granger, D.N. Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front. Biosci., 2004, 9, 1339-1347.
38. Yemisci, M.; Gursoy-Ozdemir, Y.; Vural, A.; Can, A.; Topalkara, K.; Dalkara, T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat. Med., 2009, 15, 1031-1037.
39. Lindsberg, P.J., Strbian, D.; Karjalainen-Lindsberg, M.L. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J. Cereb. Blood Flow Metab., 2010, 30, 689-702.
40. Amantea, D.; Russo, R.; Gliozzi, M.; Fratto, V.; Berliocchi, L.; Bagetta, G.; Bernardi, G.; Corasaniti, M.T. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int. Rev. Neurobiol., 2007, 82, 149-169.
41. Amantea, D.; Bagetta, G.; Tassorelli, C.; Mercuri, N.B.; Corasaniti M.T. Identification of distinct cellular pools of interleukin-1 during the evolution of the neuroinflammatory response induced by transient middle cerebral artery occlusion in the brain of rat. Brain Res., 2010, 1313, 259-269.
42. Verkhratsky, A.; Parpura, V. Recent advances in (patho)physiology of astroglia. Acta Pharmacol. Sin., 2010, 31, 1044-1054.
43. Abbott, N.J.; Revest, P.A.; Romero, I.A. Astrocyte-endothelial interaction: physiology and pathology. Neuropathol. Appl. Neurobiol., 1992, 8, 424-433.
44. Dodson, R.F.; Chu, L.W.; Welch, K.M.; Achar, V.S. Acute tissue response to cerebral ischemia in the gerbil: an ultrastructural study. J. Neurol. Sci., 1977, 33, 161-170.
45. Tuttolomondo, A.; Di Raimondo, D.; di Sciacca, R.; Pinto, A.; Licata, G. Inflammatory cytokines in acute ischemic stroke. Curr. Pharm. Des., 2008, 14, 3574-3589.
46. Sofroniew, M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci., 2009, 32, 638-647.
47. Kuboyama, K.; Harada, H.; Tozaki-Saitoh, H.; Tsuda, M.; Ushijima, K.; Inoue, K. Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia. J. Cereb. Blood Flow Metab., 2011, 31, 1930-1941.
48. Fang, S.H.; Wei, E.Q.; Zhou, Y.; Wang, M.L.; Zhang, W.P.; Yu, G.L.; Chu, L.S.; Chen, Z. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience, 2006, 140, 969-979.
49. Wang, W.; Redecker, C.; Yu, Z.Y.; Xie, M.J.; Tian, D.S.; Zhang, L.; Bu, B.T.; Witte, O.W. Rat focal cerebral ischemia induced astrocyte proliferation and delayed neuronal death are attenuated by cyclindependent kinase inhibition. J. Clin. Neurosci., 2008, 15, 278-285.
50. Barreto, G.; Whilte, R.E; Ouyang, Y.; Xu, L.; Giffard, R.G. Astrocytes: Targets for neuroprotection in stroke. Cent. Nerv. Syst. Agents Med. Chem., 2011, 11, 164-173.
51. Swanson, R A.; Ying, W.; Kauppinen, T.M. Astrocyte influences on ischemic neuronal death. Curr. Mol. Med., 2004, 4, 193-205.
52. Brambilla, R.; Bracchi-Ricard, V.; Hu, W.H.; Frydel, B.; Bramwell, A.; Karmally, S.; Green, E.J.; Bethea, J.R. Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J. Exp. Med., 2005, 202, 145-156.
53. Shen, L.H.; Li, Y.; Gao, Q.; Savant-Bhonsale, S.; Chopp, M. Down-regulation of neurocan expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain. Glia, 2008, 56, 1747-1754.
54. Zador, Z.; Stiver, S.; Wang, V.; Manley, G.T. Role of aquaporin-4 in cerebral edema and stroke. Handb. Exp. Pharmacol., 2009, 190, 159-170.
55. Hoehn, B.; Ringer, T.M.; Xu, L.; Giffard, R.G.; Sapolsky, R.M.; Steinberg, G.K.; Yenari, M.A. Overexpression of HSP72 after induction of experimental stroke protects neurons from ischemic damage. J. Cereb. Blood Flow Metab., 2001, 21, 1303-1309.
56. Dvoriantchikova, G.; Barakat, D.; Brambilla, R.; Agudelo, C.; Hernandez, E.; Bethea, J.R.; Shestopalov, VI.; Ivanov, D. Inactivation of astroglial NF-kappa B promotes survival of retinal neurons following ischemic injury. Eur. J. Neurosci., 2009, 30, 175-185.
57. del Zoppo, G.J.; Hallenbeck, J.M. Advances in the vascular pathophysiology of ischemic stroke. Thromb. Res., 2000, 98, 73-81.
58. Rosenberg, G.A.; Estrada, E.Y.; Dencoff, J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke, 1998, 29, 2189-2195.
59. Rossi, D.J.; Brady, J.D.; Mohr, C. Astrocyte metabolism and signaling during brain ischemia. Nat. Neurosci., 2007, 10, 1377-1386.
60. Stanimirovic, D.B.; Ball, R.; Durkin, J.P. Stimulation of glutamate uptake and Na,K-ATPase activity in rat astrocytes exposed to ischemia-like insults. Glia, 1997, 19, 123-134.
61. Kinoshita, A.; Yamada, K.; Kohmura, E.; Hayakawa, T. Effect of astrocyte-derived factors on ischemic brain edema induced by rat MCA occlusion. APMIS, 1990, 98, 851-857.
62. del Zoppo, G.J. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience, 2009, 158, 972-982.
63. Shen, L.H.; Li, Y.; Chopp, M. Astrocytic endogenous glial cell derived neurotrophic factor production is enhanced by bone marrow stromal cell transplantation in the ischemic boundary zone after stroke in adult rats. Glia, 2010, 58, 1074-1081.
64. Ouyang, Y.B.; Voloboueva, L.A.; Xu, L.J.; Giffard, R.G. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J. Neurosci., 2007, 27, 4253-4260.
65. Nawashiro, H.; Brenner, M.; Fukui, S.; Shima, K.; Hallenbeck ,J.M. High susceptibility to cerebral ischemia in GFAP-null mice. J. Cereb. Blood Flow Metab., 2000, 20, 1040-1044.
66. Sofroniew, M.V. Reactive astrocytes in neural repair and protection. Neuroscientist, 2005, 11, 400-407.
67. Li, L.; Lundkvist, A.; Andersson, D.; Wilhelmsson, U.; Nagai, N.; Pardo, A.C.; Nodin, C.; Ståhlberg, A.; Aprico, K.; Larsson, K.; Yabe, T.; Moons, L.; Fotheringham, A.; Davies, I.; Carmeliet, P.; Schwartz, J.P.; Pekna, M.; Kubista, M.; Blomstrand, F.; Maragakis, N.; Nilsson, M.; Pekny, M. Protective role of reactive astrocytes in brain ischemia. J. Cereb. Blood Flow Metab., 2008, 28, 468-481.
68. Hayakawa, K.; Nakano, T.; Irie, K.; Higuchi, S.; Fujioka, M.; Orito, K.; Iwasaki, K.; Jin, G.; Lo, E.H.; Mishima, K.; Fujiwara, M.J. Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab., 2010, 30, 871-882.
69. Nakase, T.; Fushiki, S.; Naus, C.C. Astrocytic gap junctions composed of connexin 43 reduce apoptotic neuronal damage in cerebral ischemia. Stroke, 2003, 34, 1987-1993.
70. Keiner, S.; Wurm, F.; Kunze, A.; Witte, O.W.; Redecker, C. Rehabilitative therapies differentially alter proliferation and survival of glial cell populations in the perilesional zone of cortical infarcts. Glia, 2008, 56, 516-527.
71. Amantea, D.; Tassorelli, C.; Russo, R.; Petrelli, F.; Morrone, L.A.; Bagetta, G.; Corasaniti, M.T. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain. Cell Death Dis., 2011, 8, 2: e238.
72. Bezzi, P.; Domercq, M.; Brambilla, L.; Galli, R.; Schols, D.; De Clercq, E.; Vescovi, A.; Bagetta, G.; Kollias, G.; Meldolesi, J.; Volterra, A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci., 2001, 4, 702-710.
73. Kang, S.S.; Keasey, M.P.; Cai, J.; Hagg, T. Loss of neuronastroglial interaction rapidly induces protective CNTF expression after stroke in mice. J. Neurosci., 2012, 32, 9277-9287.
74. Zamanian, J.L.; Xu, L.; Foo, L.C.; Nouri, N.; Zhou, L.; Giffard, R.G.; Barres, B.A. Genomic analysis of reactive astrogliosis. J. Neurosci., 2012, 32, 6391-6410.
75. Dheen, S.T.; Kaur, C.; Ling, E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem., 2007, 14, 1189-1197.
76. Kettenmann, H.; Hanisch, U.K.; Noda, M.; Verkhratsky, A. Physiology of microglia. Physiol. Rev., 2011, 91, 461-553.
77. Jung, S.; Schwartz, M. Non-identical twins - microglia and monocyte- derived macrophages in acute injury and autoimmune inflammation. Front. Immunol., 2012, 3, 89.
78. Ekdahl, C.T.; Kokaia, Z.; Lindvall, O. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience, 2009, 158, 1021-1029.
79. Battista, D.; Ferrari, C.C.; Gage, F.H.; Pitossi, F.J. Neurogenic niche modulation by activated microglia: transforming growth factor beta increases neurogenesis in the adult dentate gyrus. Eur. J. Neurosci., 2006, 23, 83-93.
80. Ziv, Y.; Ron, N.; Butovsky, O.; Landa, G.; Sudai, E.; Greenberg, N.; Cohen, H.; Kipnis, J.; Schwart, M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci., 2006, 9, 268-275.
81. Thored, P.; Heldmann, U.; Gomes-Leal, W.; Gisler, R.; Darsalia, V.; Taneera, J.; Nygren, J.M.; Jacobsen, S.E.; Ekdahl, C.T.; Kokaia, Z.; Lindvall, O. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia, 2009, 57, 835-849.
82. Wake, H.; Moorhouse, A.J.; Jinno, S.; Kohsaka, S.; Nabekura, J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci., 2009, 29, 3974-3980.
83. Kettenmann, H.; Kirchhoff, F.; Verkhratsky, A. Microglia: new roles for the synaptic stripper. Neuron, 2013, 77, 10-18.
84. Checchin, D.; Sennlaub, F.; Levavasseur, E.; Leduc, M.; Chemtob, S. Potential role of microglia in retinal blood vessel formation. Invest. Ophthalmol. Vis. Sci., 2006, 47, 3595-3602.
85. Eyo, U.B.; Dailey, M.E. Microglia: Key Elements in Neural Development, Plasticity, and Pathology. J. Neuroimmune Pharmacol., 2013, 8, 494-509.
86. Caldero, J.; Brunet, N.; Ciutat, D.; Hereu, M.; Esquerda, J.E. Development of microglia in the chick embryo spinal cord: implications in the regulation of motoneuronal survival and death. J. Neurosci. Res., 2009, 87, 2447-2466.
87. Schilling, M.; Besselmann, M.; Muller, M.; Strecker, J.K.; Ringelstein, E.B.; Kiefer, R. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol., 2005, 196, 290-297.
88. Dénes, A.; Vidyasagar, R.; Feng, J.; Narvainen, J.; McColl, B.W.; Kauppinen, R.A.; Allan, S.M. Proliferating resident microglia after focal cerebral ischaemia in mice. J. Cereb. Blood Flow Metab., 2007, 27, 1941-1953.
89. Volonté, C.; Amadio, S.; Cavaliere, F.; D'Ambrosi, N.; Vacca, F.; Bernardi, G. Extracellular ATP and neurodegeneration. Curr. Drug Targets CNS Neurol. Disord., 2003, 2, 403-412.
90. Melani, A.; Amadio, S.; Gianfriddo, M.; Vannucchi, M.G.; Volontè, C.; Bernardi, G.; Pedata, F.; Sancesario, G. P2X7 receptor modulation on microglial cells and reduction of brain infarct caused by middle cerebral artery occlusion in rat. J. Cereb. Blood Flow Metab., 2006, 26, 974-982.
91. Melani, A.; Corti, F.; Stephan, H.; Müller, C.E.; Donati, C.; Bruni, P.; Vannucchi, M.G.; Pedata, F. Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. Exp. Neurol., 2012, 233, 193-204.
92. Amantea, D.; Fratto, V.; Maida, S.; Rotiroti, D.; Ragusa, S.; Nappi, G.; Bagetta, G.; Corasaniti M.T. Prevention of glutamate accumulation and upregulation of phospho-Akt may account for neuroprotection afforded by bergamot essential oil against brain injury induced by focal cerebral ischemia in rat. Int. Rev. Neurobiol., 2009, 85, 389-405.
93. Pocock, J.M., Kettenmann, H. Neurotransmitter receptors on microglia. Trends Neurosci., 2007, 30, 527-535.
94. Mead, E.L.; Mosley, A.; Eaton, S.; Dobson, L.; Heales, S.J.; Pocock, J.M. Microglial neurotransmitter receptors trigger superoxide production in microglia; consequences for microglial-neuronal interactions. J. Neurochem., 2012, 121, 287-301.
95. Davies, C.A.; Loddick, S.A.; Toulmond, S.; Stroemer, R.P.; Hunt, J.; Rothwell, N.J. The progression and topographic distribution of interleukin-1 beta expression after permanent middle cerebral artery occlusion in the rat. J. Cereb. Blood Flow Metab., 1999, 19, 87-98.
96. Kato, H.; Kogure, K.; Liu, X.H.; Araki, T.; Itoyama, Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res., 1996, 734, 203-212.
97. Zhang, Z.; Chopp, M.; Powers, C. Temporal profile of microglial response following transient (2h) middle cerebral artery occlusion. Brain Res., 1997, 744, 189-198.
98. Stoll, G.; Jander, S.; Schroeter, M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol., 1998, 56, 149-171.
99. Gerhard, A.; Schwarz, J.; Myers, R.; Wise, R.; Banati, R.B. Evolution of microglial activation in patients after ischemic stroke: a [11C] (R)-PK11195 PET study. Neuroimage, 2005, 24, 591-595.
100. Price, C.J.; Wang, D,; Menon, D.K;, Guadagno, J.V.; Cleij, M.; Fryer, T.; Aigbirhio, F.; Baron, J.C.; Warburton, E.A. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke, 2006, 37, 1749-1753.
101. Davis, E.J.; Foster, T.D.; Thomas, W.E. Cellular forms and functions of brain microglia. Brain Res. Bull., 1994, 34, 73-78.
102. Schilling, M.; Besselmann, M.; Leonhard, C.; Mueller, M.; Ringelstein, E.B.; Kiefer, R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp. Neurol., 2003, 183, 25-33.
103. Barone, F.C.; Arvin, B.; White, R.F.; Miller, A.; Webb, C.L.; Willette, R.N.; Lysko, P.G.; Feuerstein, G.Z. Tumor necrosis factoralpha. A mediator of focal ischemic brain injury. Stroke, 1997, 28, 1233-1244.
104. Lambertsen, K.L.; Meldgaard, M.; Ladeby, R.; Finsen, B. A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab., 2005, 25, 119-135.
105. Rothwell, N.; Allan, S.; Toulmond, S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J. Clin. Invest., 1997, 100, 2648-2652.
106. Green, S.P.; Cairns, B.; Rae J.; Erret-Baroncini, C.; Hongo, J.A.; Erickson, R.W.; Curnutte, J.T. Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. J. Cereb. Blood Flow Metab., 2001, 21, 374-384.
107. Wang, J.Y.; Wen, L.L.; Huang, Y.N.; Chen, Y.T.; Ku, M.C. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharm. Des., 2006, 12, 3521-3533.
108. del Zoppo, G.J.; Milner R.; Mabuchi T.; Hung, S.; Wang, X.; Berg, G.I.; Koziol, J.A. Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke, 2007, 38, 646-651.
109. Fagan, S.C.; Cronic, L.E.; Hess, D.C. Minocycline Development for Acute Ischemic Stroke. Transl. Stroke Res., 2011, 2, 202-208.
110. Hailer, N.P. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog. Neurobiol., 2008, 84, 211-233.
111. Yrjanheikki, J.; Tikka, T.; Keinanen, R.; Goldsteins, G.; Chan, P.H.; Koistinaho, J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. USA, 1999, 96, 13496-13500.
112. Zhang, L.; Dong, LY.; Li, Y.J.; Hong, Z.; Wei, W.S. The microRNA miR-181c controls microglia-mediated neuronal apoptosis by suppressing tumor necrosis factor. J. Neuroinflammation, 2012, 9, 211.
113. Lehnardt, S.; Massillon, L.; Follett, P.; Jensen, F.E.; Ratan, R.; Rosenberg, P.A.; Volpe, J.J.; Vartanian, T. Activation of innate immunity in the CNS triggers neurodegeneration through a Tolllike receptor 4-dependent pathway. Proc. Natl. Acad. Sci. USA, 2003, 100, 8514-8519.
114. Dénes, A.; Ferenczi, S.; Halász, J.; Környei, Z.; Kovács, K.J. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J. Cereb. Blood Flow Metab., 2008, 28, 1707-1721.
115. Dentesano, G.; Straccia, M.; Ejarque-Ortiz, A.; Tusell, J.M.; Serratosa, J.; Saura, J.; Solà, C. Inhibition of CD200R1 expression by C/EBP beta in reactive microglial cells. J. Neuroinflammation, 2012, 9, 165.
116. Patel, K.D.; Davison, J.S.; Pittman, Q.J.; Sharkey, K.A. Cannabinoid CB(2) receptors in health and disease. Curr. Med. Chem., 2010, 17, 1393-1410.
117. Zarruk, J.G.; Fernández-López, D.; García- Yébenes, I.; García- Gutiérrez, M.S.; Vivancos, J.; Nombela, F.; Torres, M.; Burguete, M.C.; Manzanares, J.; Lizasoain, I.; Moro, M.A. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke, 2012, 43, 211-219.
118. Sieber, M.W.; Jaenisch, N.; Brehm, M.; Guenther, M.; Linnartz- Gerlach, B.; Neumann, H.; Witte, O.W.; Frahm, C. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knouck-out mice following stroke. PLoS One, 2013, 8, e52982.
119. O'Donnell, S.L.; Frederick, T.J.; Krady, J.K.; Vannucci, S.J.; Wood, T.L. IGF-I and microglia/macrophage proliferation in the ischemic mouse brain. Glia, 2002, 39, 85-97.
120. Lalancette-Hébert, M.; Gowing, G.; Simard, A.; Weng, Y.C.; Kriz, J. Selective ablation of proliferating microglia cells exacerbates ischemic injury in the brain. J. Neurosci., 2007, 27, 2596-2605.
121. Neumann, J.; Sauerzweig, S.; Rönicke, R.; Gunzer, F.; Dinkel, K.; Ullrich, O.; Gunzer, M.; Reymann, K.G. Microglia cells protect neurons by direct engulfment of invading neutrophil granulocytes: a new mechanism of CNS immune privilege. J. Neurosci., 2008, 28, 5965-5975.
122. Ransohoff, R.M.; Perry, V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol., 2009, 27, 119-145.
123. Ransohoff, R.M.; Cardona, A.E. The myeloid cells of the central nervous system parenchyma. Nature, 2010, 468, 253-262.
124. Lalancette-Hébert, M.; Swarup, V.; Beaulieu, J.M.; Bohacek, I.; Abdelhamid, E.; Weng, Y.C.; Sato, S.; Kriz, J. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J. Neurosci., 2012, 32, 10383-10395.
125. Imai, F.; Suzuki, H.; Oda, J.; Ninomiya, T.; Ono, K.; Sano, H.; Sawada, M. Neuroprotective effect of exogenous microglia in global brain ischemia. J. Cereb. Blood Flow Metab., 2007, 27, 488-500.
126. Kitamura, Y.; Takata, K.; Inden, M.; Tsuchiya, D.; Yanagisawa, D.; Nakata, J.; Taniguchi, T. Intracerebroventricular injection of microglia protects against focal brain ischemia. J. Pharmacol. Sci., 2004, 94, 203-206.
127. Clausen, B.H.; Lambertsen, K.L.; Babcock, A.A.; Holm, T.H.; Dagnaes-Hansen, F.; Finsen, B. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke mice. J. Neuroinflamm., 2008, 5, 46.
128. Perego, C.; Fumagalli, S.; De Simoni, M.G. Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J. Neuroinflamm., 2011, 8, 174.
129. Perry, V.H.; Nicoll, J.A.; Holmes, C. Microglia in neurodegenerative disease. Nat. Rev. Neurol., 2010, 6, 193-201.
130. Hu, X.; Li, P.; Guo, Y.; Wang, H.; Leak, R.K.; Chen, S.; Gao, Y.; Chen, J. Microglia/Macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke, 2012, 43, 3063-3070.
131. Xu, Y.; Qian, L.; Zong, G.; Ma, K.; Zhu, X.; Zhang, H.; Li, N.; Yang, Q.; Bai, H.; Ben, J.; Li, X.; Xu, Y.; Chen, Q. Class A scavenger receptor promotes cerebral ischemic injury by pivoting microglia/ macrophage polarization. Neuroscience, 2012, 218, 35-48.
132. Frieler, R.A.; Meng, H.; Duan, S.Z.; Berger, S.; Schütz, G.; He, Y.; Xi, G.; Wang, M.M.; Mortensen, R.M. Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke, 2011, 42, 179-185.
133. Huang, Y.C.; Feng, Z.P. The good and bad of microglia/ macrophages: new hope in stroke therapeutics. Acta Pharmacol. Sin., 2013, 36, 6-7.
134. Price, C.J.; Menon, D.K.; Peters, A.M.; Ballinger, J.R.; Barber, R.W.; Balan, K.K.; Lynch, A.; Xuereb, J.H.; Fryer, T.; Guadagno, J.V. Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke, 2004, 35, 1659-1664.
135. Buck, B.H.; Liebeskind, D.S.; Saver, J.L.; Bang, O.Y.; Yun, S.W.; Starkman, S.; Ali, L.K.; Kim, D.; Villablanca, J.P.; Salamon, N.; Razinia, T.; Ovbiagele, B. Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke, 2008, 39, 355-360.
136. Felger, J.; Abe, T.; Kaunzner, U.; Gottfried-Blackmore, A.; Gal- Toth, J.; McEwen, B.; Iadecola, C.; Bulloch, K. Brain dendritic cells in ischemic stroke: time course, activation state, and origin. Brain Behav. Immun., 2010, 24, 724-737.
137. Kamel, H.; Iadecola, C. Brain-immune interactions and ischemic stroke. Clinical implications. Arch. Neurol., 2012, 69, 576-581.
138. Chen, G.Y.; Nuñez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol., 2010, 10, 826-837.
139. Konsman, J.P.; Drukarch, B.; Van Dam, A.M. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin. Sci. (Lond.), 2007, 112, 1-25.
140. Huang, J.; Upadhyay, U.M.; Tamargo, R.J. Inflammation in stroke and focal cerebral ischemia. Surg. Neurol., 2006, 66, 232-245.
141. Garcia, J.H.; Liu, K.F.; Yoshida, Y.; Lian, J.; Chen, S.; del Zoppo, G.J. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am. J. Pathol., 1994, 144, 188-199.
142. lark, R.K.; Lee, E.V.; White, R.F.; Jonak, Z.L.; Feuerstein, G.Z.; Barone, F.C. Reperfusion following focal stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res. Bull., 1994, 35, 387-392.
143. Gelderblom, M.; Leypoldt, F.; Steinbach, K.; Behrens, D.; Choe, C.U.; Siler, D.A.; Arumugam, T.V.; Orthey, E.; Gerloff, C.; Tolosa, E.; Magnus, T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke, 2009, 40, 1849-1857.
144. Matsuo, Y.; Onodera, H.; Shiga, Y.; Shozuhara, H.; Ninomiya, M.; Kihara, T.; Tamatani, T.; Miyasaka, M.; Kogure, K. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res., 1994, 656, 344-352.
145. Matsuo, Y.; Onodera, H.; Shiga, Y.; Nakamura, M.; Ninomiya, M.; Kihara, T.; Kogure, K. Correlation between myeloperoxidasequantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke, 1994, 25, 1469-1475.
146. Connolly, E.S. Jr; Winfree, C.J.; Springer, T.A.;, Naka, Y.; Liao, H.; Yan, S.D.; Stern, D.M.; Solomon, R.A.; Gutierrez-Ramos, J.C.; Pinsky, D.J. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J. Clin. Invest., 1996, 97, 209-216.
147. Atochin, D.N.; Fisher, D.; Demchenko, I.T.; Thom, S.R. Neutrophil sequestration and the effect of hyperbaric oxygen in a rat model of temporary middle cerebral artery occlusion. Undersea Hyperb. Med., 2000, 27, 185-190.
148. del Zoppo, G.J.; Schmid-Schonbein, G.W.; Mori, E.; Copeland, B.R.; Chang, C.M. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke, 1991, 22, 1276-1283.
149. Ritter, L.S.; Stempel, K.M.; Coull, B.M.; McDonagh, P.F. Leukocyte- platelet aggregates in rat peripheral blood after ischemic stroke and reperfusion. Biol. Res. Nurs., 2005, 6, 281-288.
150. Justicia, C.; Panés, J.; Solé, S.; Cervera, A.; Deulofeu, R.; Chamorro, A.; Planas, A.M. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/ reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab., 2003, 23, 1430-1440.
151. Gidday, J.M.; Gasche, Y.G.; Copin, J.C.; Shah, A.R.; Perez, R.S.; Shapiro, S.D.; Chan, P.H.; Park, T.S. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol., 2005, 289, H558-H568.
152. Aizawa, H.; Makita, Y.; Sumitomo, K.; Aburakawa, Y.; Katayama, T.; Nakatani-Enomoto, S.; Suzuki, Y.; Fujiwara, K.; Enomoto, H.; Kuroda, K.; Kimura, T.; Yahara, O.; Koyama, S.; Maruyama, J.; Nakamura, M.; Hasebe, N.; Kikuchi, K. Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack. Intern. Med., 2006, 45, 1-4.
153. Bao Dang, Q.; Lapergue, B.; Tran-Dinh, A.; Diallo, D.; Moreno, J.A.; Mazighi, M.; Romero, I.A.; Weksler, B.; Michel, J.B.; Amarenco, P.; Meilhac, O. High-density lipoproteins limit neutrophil- induced damage to the blood-brain barrier in vitro. J. Cereb. Blood Flow Metab., 2013, 33, 575-582.
154. Tanaka, R.; Komine-Kobayashi, M.; Mochizuki, H.; Yamada, M.; Furuya, T.; Migita, M.; Shimada, T.; Mizuno, Y.; Urabe, T. Migration of enhanced green fluorescent protein expressing bone marrow- derived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience, 2003, 117, 531-539.
155. Jander, S.; Schroeter, M.; Saleh, A. Imaging inflammation in acute brain ischemia. Stroke, 2007, 38, 642-645.
156. Martinez, F.O.; Helming, L.; Gordon, S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol., 2009, 27, 451-483.
157. Shechter, R.; Schwartz, M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. J. Pathol., 2013, 229, 332-346.
158. Gliem, M.; Mausberg, A.K.; Lee, J.I.; Simiantonakis, I.; Rooijen, N.; Hartung, H.P.; Jander, S. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann. Neurol., 2012, 71, 743-752.
159. Steinman, R.M.; Banchereau, J. Taking dendritic cells into medicine. Nature, 2007, 449, 419-426.
160. Kostulas, N.; Li, H.L.; Xiao, B.G.; Huang, Y.M.; Kostulas, V.; Link, H. Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. Stroke, 2002, 33, 1129-1134.
161. Reichmann, G.; Schroeter, M.; Jander, S.; Fischer, H.G. Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J. Neuroimmunol., 2002, 129, 125-132.
162. Gottfried-Blackmore, A.; Kaunzner, U.; Idoyaga, J.; Felger, J.; McEwen, B.; Bulloch, K. Acute in vivo exposure to interferongamma enables resident brain dendritic cells to become effective antigen presenting cells. Proc. Natl. Acad. Sci. USA, 2009, 106, 20918-20923.
163. Jander, S.; Kraemer, M.; Schroeter, M.; Witte, O.; Stoll, G. Lymphocytic infiltration and expression of intercellular adhesion molecule- 1 in photochemically induced ischemia of the rat cortex. J. Cereb. Blood Flow Metab., 1995, 15, 42-51.
164. Schwab, J.M.; Nguyen, T.D.; Meyermann, R.; Schluesener, H.J. Human focal cerebral infarctions induce differential lesional interleukin- 16 (IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J. Neuroimmunol., 2001, 114, 232-241.
165. Yilmaz, G.; Arumugam, T.V.; Stokes, K.Y.; Granger, D.N. Role of T lymphocytes and interferon- in ischemic stroke. Circulation, 2006, 113, 2105-2112.
166. Hurn, P.D.; Subramanian, S.; Parker, S.M.; Afentoulis, M.E.; Kaler, L.J.; Vandenbark, A.A.; Offner, H. T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J. Cereb. Blood Flow Metab., 2007, 27, 1798-1805.
167. Jin, R.; Yang, G.; Li, G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J. Leukoc. Biol., 2010, 87, 779-789.
168. Gu, L.; Xiong, X.; Zhang, H.; Xu, B.; Steiberg, G.K.; Zhao, H. Distinctive effects of T cell subsets in neuronal injury induced by cocultured splenocytes in vitro and by in vivo stroke in mice. Stroke, 2012, 43, 1941-1946.
169. Becker, K.; Kindrick, D.; Relton, J.; Harlan, J.; Winn, R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke, 2001, 32, 206-211.
170. Relton, J.K.; Sloan, K.E.; Frew, E.M.; Whalley, E.T.; Adams, S.P.; Lobb, R.R. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke, 2001, 32, 199-205.
171. Kleinschnitz, C.; Schwab, N.; Kraft, P.; Hagedorn, I.; Dreykluft, A.; Schwarz, T.; Austinat, M.; Nieswandt, B.; Wiendl, H.; Stoll, G. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood, 2010, 115, 3835-3842.
172. Frenkel, D.; Huang, Z.; Maron, R.; Koldzic, D.N.; Moskowitz, M.A.; Weiner, H.L. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J. Neurol. Sci., 2005, 233, 125-132.
173. Liesz, A.; Suri-Payer, E.; Veltkamp, C.; Doerr, H.; Sommer, C.; Rivest, S.; Giese, T.; Veltkamp, R. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat. Med., 2009, 15, 192-199.
174. Zhu, P.; Hata, R.; Ogasawara, M.; Cao, F.; Kameda, K.; Yamauchi, K.; Schinkel, A.H.; Maeyama, K.; Sakanaka, M. Targeted disruption of organic cation transporter 3 (Oct3) ameliorates ischemic brain damage through modulating histamine and regulatory T cells. J. Cereb. Blood Flow Metab., 2012, 32, 1897-1908.
175. Chen, Y.; Ruetzler, C.; Pandipati, S.; Spatz, M.; McCarron, R.M.; Becker, K.; Hallenbeck, J.M. Mucosal tolerance to Eselectin provides cell-mediated protection against ischemic brain injury. Proc. Natl. Acad. Sci. USA, 2003, 100, 15107-15112.
176. Nakayama, T.; Illoh, K.; Ruetzler, C.; Auh, S.; Sokoloff, L.; Hallenbeck, J. Intranasal administration of E-selectin to induce immunological tolerization can suppress subarachnoid hemorrhageinduced vasospasm implicating immune and inflammatory mechanisms in its genesis. Brain Res., 2007, 1132, 177-184.
177. Takeda, H.; Spatz, M.; Ruetzler, C.; McCarron, R.; Becker, K.; Hallenbeck, J. Induction of mucosal tolerance to E-selectin targets immunomodulation to activating vessel segments and prevents ischemic and hemorrhagic stroke. Ernst Schering Res. Found. Workshop, 2004, 47, 117-132.
178. Wakita, H.; Ruetzler, C.; Illoh, K.O.; Chen, Y.; Takanohashi, A.; Spatz, M.; Hallenbeck, J.M. Mucosal tolerization to E-selectin protects against memory dysfunction and white matter damage in a vascular cognitive impairment model. J. Cereb. Blood Flow Metab., 2008, 28, 341-353.
179. Ishibashi, S.; Maric, D.; Mou, Y.; Ohtani, R.; Ruetzler, C.; Hallenbeck, J.M. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. J. Cereb. Blood Flow Metab., 2009, 29, 606-620.
180. Kleinschnitz, C.; Kraft, P.; Dreykluft, A.; Hagedorn, I.; Göbel, K.; Schuhmann, M.K.; Langhauser, F.; Helluy, X.; Schwarz, T.; Bittner, S.; Mayer, C.T.; Brede, M.; Varallyay, C.; Pham, M.; Bendszus, M.; Jakob, P.; Magnus, T.; Meuth, S.G.; Iwakura, Y.; Zernecke, A.; Sparwasser, T.; Nieswandt, B.; Stoll, G.; Wiendl, H. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood, 2013, 121, 679-691.
181. Offner, H.; Subramanian, S.; Parker, S.M.; Wang, C.; Afentoulis, M.E.; Lewis, A.; Vandenbark, A.A.; Hurn, P.D. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J. Immunol., 2006, 176, 6523-6531.
182. Yan, J.; Greer, J.M.; Etherington, K.; Cadigan, G.P.; Cavanagh, H.; Henderson, R.D.; O'Sullivan, J.D.; Pandian, J.D.; Read, S.J.; McCombe, P.A. Immune activation in the peripheral blood of patients with acute ischemic stroke. J. Neuroimmunol., 2009, 206, 112-117.
183. Brait, V.H.; Arumugam, T.V.; Drummond, G.R.; Sobey, C.G. Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia. J. Cereb. Blood Flow Metab., 2012, 32, 598-611.
184. Shichita, T.; Sugiyama, Y.; Ooboshi, H.; Sugimori, H.; Nakagawa, R.; Takada, I.; Iwaki, T.; Okada, Y.; Iida, M.; Cua, D.J.; Iwakura, Y.; Yoshimura, A. Pivotal role of cerebral interleukin-17-producing Tcells in the delayed phase of ischemic brain injury. Nat. Med., 2009, 15, 946-50.
185. Swardfager, W.; Winer, D.A.; Herrmann, N.; Winer, S.; Lanctôt, K.L. Interleukin-17 in post-stroke neurodegeneration. Neurosci. Biobehav. Rev., 2013, 37, 436-447.
186. Hasegawa, Y.; Suzuki, H.; Sozen, T.; Rolland, W.; Zhang, J.H. Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats. Stroke, 2010, 41, 368-374.
187. Wei, Y.; Yemisci, M.; Kim, H.H.; Yung, L.M.; Shin, H.K.; Hwang, S.K.; Guo, S.; Qin, T.; Alsharif, N.; Brinkmann, V.; Liao, J.K; Lo, E.H; Waeber, C. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann. Neurol., 2011, 69, 119-129.
188. Rolland, W.B.; Lekic, T.; Krafft, P.R.; Hasegawa, Y.; Altay, O.; Hartman, R.; Ostrowski, R.; Manaenko, A.; Tang, J.; Zhang, J.H. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp. Neurol., 2013, 241, 45-55.
189. Liesz, A.; Sun, L.; Zhou, W.; Schwarting, S.; Mracsko, E.; Zorn, M.; Bauer, H.; Sommer, C.; Veltkamp, R. FTY720 reduces postischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia. PLoS ONE, 2011, 6, e21312.
190. Meisel, C.; Meisel, A. Suppressing immunosuppression after stroke. N. Engl. J. Med., 2011, 365, 2134-2136.
191. Pfeilschifter, W.; Czech-Zechmeister, B.; Sujak, M.; Foerch, C.; Wichelhaus, T.A.; Pfeilschifter, J. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp. Transl. Stroke Med., 2011, 9, 3-2.
192. Brough, D.; Le Feuvre, R.A.; Iwakura, Y.; Rothwell, N.J. Purinergic (P2X7) receptor activation of microglia induces cell death via an interleukin-1-independent mechanism. Mol. Cell. Neurosci., 2002, 19, 272-280.
193. Volonté, C.; Apolloni, S.; Skaper, S.D.; Burnstock, G. P2X7 receptors: channels, pores and more. CNS Neurol. Disord. Drug Targets, 2012, 11, 705-721.
194. Arbeloa, J.; Pérez-Samartín, A.; Gottlieb, M.; Matute, C. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol. Dis., 2012, 45, 954-961.
195. Domercq, M.; Perez-Samartin, A.; Aparicio, D.; Alberdi, E.; Pampliega, O.; Matute, C. P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia, 2010, 58, 730-740.
196. Fossati, S.; Chiarugi, A. Relevance of high-mobility group protein box 1 to neurodegeneration. Int. Rev. Neurobiol., 2007, 82, 137-148.
197. Shichita, T.; Ago, T.; Kamouchi, M.; Kitazono, T.; Yoshimura, A.; Ooboshi, H. Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke. J. Neurochem., 2012, 123, 29-38.
198. Shichita, T.; Hasegawa, E.; Kimura, A.; Morita, R.; Sakaguchi, R.; Takada, I.; Sekiya, T.; Ooboshi, H.; Kitazono, T.; Yanagawa, T.; Ishii, T.; Takahashi, H.; Mori, S.; Nishibori, M.; Kuroda, K.; Akira, S.; Miyake, K.; Yoshimura, A. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat. Med., 2012, 18, 911-917.
199. Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Lorenzo, P.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation, 2007, 115, 1599-1608.
200. Ziegler, G.; Harhausen, D.; Schepers, C.; Hoffmann, O.; Rohr, C.; Prinz, V.; Konig, J.; Lehrach, H.; Nietfeld, W.; Trendelenburg, G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem. Biophys. Res. Commun., 2007, 359, 574-579.
201. Brea, D.; Blanco, M.; Ramos-Cabrer, P.; Moldes, O.; Arias, S.; Pérez-Mato, M.; Leira, R.; Sobrino, T.; Castillo, J. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J. Cereb. Blood Flow Metab., 2011, 31, 1424-1431.
202. Tang, S.C.; Arumugam, T.V.; Xu, X.; Cheng, A.; Mughal, M.R.; Jo, D.G.; Lathia, J.D.; Siler, D.A.; Chigurupati, S.; Ouyang, X.; Magnus, T.; Camandola, S.; Mattson, M.P. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl. Acad. Sci. USA, 2007, 104, 13798-13803.
203. Hyakkoku, K., Hamanaka, J., Tsuruma, K., Shimazawa, M., Tanaka, H., Uematsu, S., Akira, S., Inagaki, N., Nagai, H.; Hara H. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience, 2010, 171, 258-267.
204. Cao, C.X.; Yang, Q.W.; Lv, F.L.; Cui, J.; Fu, H.B.; Wang, J.Z. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem. Biophys. Res. Comm., 2007, 353, 509-514.
205. Hua, F.; Ma, J.; Ha, T.; Xia, Y.; Kelley, J.; Williams, D.L.; Kao, R.L.; Browder, I.W.; Schweitzer, J.B.; Kalbfleisch, J.H.; Li, C. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J. Neuroimmunol., 2007, 190, 101-111.
206. Caso, J.R.; Pradillo, J.M.; Hurtado, O.; Leza, J.C.; Moro, M.A.; Lizasoain, I. Toll-like receptor4 is involved in subacute stressinduced neuroinflammation and in the worsening of experimental stroke. Stroke, 2008, 39, 1314-1320.
207. Qiu, J.; Xu, J.; Zheng, Y.; Wei, Y.; Zhu, X.; Lo, E.H.; Moskowitz, M.A.; Sims, J.R. High-mobility group box 1 promotes metalloproteinase- 9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke, 2010, 41, 2077-2082.
208. Yang, Q.W.; Lu, F.L.; Zhou, Y.; Wang, L.; Zhong, Q.; Lin, S.; Xiang, J.; Li, J.C.; Fang, C.Q.; Wang, J.Z. HMBG1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J. Cereb. Blood Flow Metab., 2011, 31, 593-605.
209. Faraco, G.; Fossati, S.; Bianchi, M.E.; Patrone, M.; Pedrazzi, M.; Sparatore, B.; Moroni, F.; Chiarugi, A. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J. Neurochem., 2007, 103, 590-603.
210. Pradillo, J.M.; Fernández-López, D.; García- Yébenes, I.; Sobrado, M.; Hurtado, O.; Moro, M.A.; Lizasoain, I. Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J. Neurochem., 2009, 109, 287-294.
211. Vartanian, K.B.; Stevens, S.L.; Marsh, B.J.; Williams-Karnesky, R.; Lessov, N.S.; Stenzel-Poore, M.P. LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J. Neuroinflammation, 2011, 8, 140.
212. Muhammad, S.; Barakat, W.; Stoyanov, S.; Murikinati, S.; Yang, H.; Tracey, K.J.; Bendszus, M.; Rossetti, G.; Nawroth, P.P.; Bierhaus, A.; Schwaninger, M. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci., 2008, 28, 12023-12031.
213. Qiu, J., Nishimura, M., Wang, Y., Sims, J.R., Qiu, S., Savitz, S.I., Salomone, S., Moskowitz, M.A. Early release of HMGB-1 from neurons after the onset of brain ischemia. J. Cereb. Blood Flow Metab., 2008, 28, 927-938.
214. Zhai, D.X.; Kong, Q.F.; Xu, W.S.; Bai, S.S.; Peng, H.S.; Zhao, K.; Li, G.Z.; Wang, D.D.; Sun, B.; Wang, J.H.; Wang, G.Y.; Li, H.L. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci. Lett., 2008, 445, 117-121.
215. Hassid, B.G.; Nair, M.N.; Ducruet, A.F.; Otten, M.L.; Komotar, R.J.; Pinsky, D.J.; Schmidt, A.M.; Yan, S.F.; Connolly, E.S. Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia. J. Clin. Neurosci., 2009, 16, 302-306.
216. Wang, L.; Zhang, X.; Liu, L.; Yang, R.; Cui, L.; Li, M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4) NF-kappaB expression. Neurosci. Lett., 2010, 471, 152-156.
217. Greco, R.; Amantea, D.; Mangione, A.S.; Petrelli, F.; Gentile, R.; Nappi, G.; Blandini, F.; Corasaniti, M.T.; Tassorelli, C. Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. Neurochem. Res., 2012, 37, 1508-1516.
218. Hanford, L.E.; Enghild, J.J.; Valnickova, Z.; Petersen, S.V.; Schaefer, L.M.; Schaefer, T.M.; Reinhart, T.A.; Oury, T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem., 2004, 279, 50019-50024.
219. Pichiule, P.; Chavez, J.C.; Schmidt, A.M.; Vannucci, S.J. Hypoxiainducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J. Biol. Chem., 2007, 282, 36330-36340.
220. Lambertsen, K.L.; Biber, K.; Finsen, B. Inflammatory cytokines in experimental and human stroke. J. Cereb. Blood Flow Metab., 2012, 32, 1677-1698.
221. Emsley, H.C.; Smith, C.J.; Gavin, C.M.; Georgiou, R.F.; Vail, A.; Barberan, E.M.; Illingworth, K.; Scarth, S.; Wickramasinghe, V.; Hoadley, M.E.; Rothwell, N.J.; Tyrrell, P.J.; Hopkins, S.J. Clinical outcome following acute ischaemic stroke relates to both activation and autoregulatory inhibition of cytokine production. BMC Neurol., 2007, 7, 5.
222. Jickling, G.C.; Sharp, F.R. Blood biomarkers of ischemic stroke. Neurotherapeutics, 2011, 8, 349-360.
223. Rothwell, N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav. Immunity, 2003, 17, 152-157.
224. Dénes, A.; Pinteaux, E.; Rothwell, N.J.; Allan, S.M. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic target. Cerebrovasc. Dis., 2011, 32, 517-527.
225. Olsson, S.; Holmegaard, L.; Jood, K.; Sjögren, M.; Engström, G.; Lövkvist, H.; Blomstrand, C.; Norrving, B.; Melander, O.; Lindgren, A.; Jern, C. Genetic variation within the interleukin-1 gene cluster and ischemic stroke. Stroke, 2012, 43, 2278-2282.
226. Liu, T.; McDonnell, P.C.; Young, P.R.; White, R.F.; Siren, A.L.; Hallenbeck, J.M.; Barone, F.C.; Feurerstein, G.Z. Interleukin-1- beta messenger RNA expression in ischemic rat cortex. Stroke, 1993, 24, 1746-1751.
227. Buttini, M.; Sauter, A.; Boddeke, H. Induction of interleukin-1beta mRNA after focal ischemia in the rat. Mol. Brain Res., 1994, 23, 126-134.
228. Wang, X.; Yue, T.L.; Barone, F.C.; White, R.F.; Gagnon, R.C.; Feuerstein, G.Z. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol. Chem. Neuropathol., 1994, 23, 103-114.
229. Luheshi, N.M.; Kovács, K.J.; Lopez-Castejon, G.; Brough, D.; Denes, A. Interleukin-1 expression precedes IL-1 after ischemic brain injury and is localised to areas of focal neuronal loss and penumbral tissues. J. Neuroinflammation, 2011, 8, 186.
230. Hara, H.; Friedlander, R.M.; Gagliardini, V.; Ayata, C.; Fink, K.; Huang, Z.; Shimizu-Sasamata, M.; Yuan, J.; Moskowitz, M.A. Inhibition of interleukin 1 converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc. Natl. Acad. Sci. USA, 1997, 94, 2007-2012.
231. Boutin, H.; LeFeuvre, R.A.; Horai, R.; Asano, M.; Iwakura, Y.; Rothwell, N.J. Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci., 2001, 21, 5528-5534.
232. Zhang, Z.; Chopp, M.; Goussev, A.; Powers, C. Cerebral vessels express interleukin 1 beta after focal cerebral ischemia. Brain Res., 1998, 784, 210-217.
233. Walton, K.M.; DiRocco, R.; Bartlett, B.A.; Koury, E.; Marcy, V.R.; Jarvis, B.; Schaefer, E.M. Bhat, R.V. Activation of p38MAPK in microglia after ischemia. J. Neurochem., 1998, 70, 1764-1767.
234. Irving, E.A.; Barone, F.C.; Reith, A.D.; Hadingham, S.J.; Parsons, A.A. Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. Brain Res., 2000, 77, 65-75.
235. Barone, F.C.; Irving, E.A.; Ray, A.M.; Lee, J.C.; Kassis, S.; Kumar, S.; Badger, A.M.; Legos, J.J.; Erhardt, J.A.; Ohlstein, E.H.; Hunter, A.J.; Harrison, D.C.; Philpott, K.; Smith, B.R.; Adams, J.L.; Parsons, A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev., 2001, 21, 129-45.
236. Simi, A.; Lerouet, D.; Pinteaux, E.; Brough, D. Mechanisms of regulation for interleukin-1 in neurodegenerative disease. Neuropharmacology, 2007, 52, 1563-1569.
237. Fantuzzi, G.; Ku, G.; Harding, M.W.; Livingston, D.J.; Sipe, J.D.; Kuida, K.; Flavell, R.A.; Dinarello, C.A. Response to local inflammation of IL-1-converting enzyme-deficient mice. J. Immunol., 1997, 158, 1818-1824.
238. Ito, A.; Mukaiyama, A.; Itoh, Y.; Nagase, H.; Thøgersen, I.B.; Enghild, J.J.; Sasaguri, Y.; Mori, Y. Degradation of interleukin 1 by matrix metalloproteinases. J. Biol. Chem., 1996, 271, 14657-14660.
239. Schönbeck, U.; Mach, F.; Libby, P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1- independent pathway of IL-1 beta processing. J. Immunol., 1998, 161, 3340-3346.
240. Herx, L.M.; Yong, V.W. Interleukin-1 beta is required for the early evolution of reactive astrogliosis following CNS lesion. J. Neuropathol. Exp. Neurol., 2001, 60, 961-971.
241. Andre, R.; Pinteaux, E.; Kimber, I.; Rothwell, N.J. Differential actions of IL-1 alpha and IL-1 beta in glial cells share common IL- 1 signalling pathways. Neuroreport, 2005, 16, 153-157.
242. Parker, L.C.; Luheshi, G.N.; Rothwell, N.J.; Pinteaux, E. IL-1 beta signalling in glial cells in wildtype and IL-1RI deficient mice. Br. J. Pharmacol., 2002, 136, 312-320.
243. Thornton, P.; Pinteaux, E.; Allan, S.M.; Rothwell, N.J. Matrix metalloproteinase-9 and urokinase plasminogen activator mediate interleukin-1-induced neurotoxicity. Mol. Cell Neurosci., 2008, 37, 135-142.
244. Ching, S.; Zhang, H.; Belevych, N.; He, L.; Lai, W.; Pu, X.A.; Jaeger, L.B.; Chen, Q.; Quan, N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci., 2007, 27, 10476-10486.
245. Thornton, P.; McColl, B.W.; Cooper, L.; Rothwell, N.J.; Allan, S.M. Interleukin-1 drives cerebrovascular inflammation via map kinase-independent pathways. Curr. Neurovasc. Res., 2011, 7, 330-340.
246. Allen, C.; Thornton, P.; Denes, A.; McColl, B.W.; Pierozynski, A.; Monestier, M.; Pinteaux, E.; Rothwell, N.J.; Allan, S.M. Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J. Immunol., 2012, 189, 381-392.
247. Tsakiri, N.; Kimber, I.; Rothwell, N.J.; Pinteaux, E. Differential effects of interleukin-1 alpha and beta on interleukin-6 and chemokines synthesis in neurones. Mol. Cell Neurosci., 2008, 38, 259-265.
248. Wheeler, R.D.; Boutin, H.; Touzani, O.; Luheshi, G.N.; Takeda, K.; Rothwell, N.J. No role for interleukin-18 in acute murine stroke-induced brain injury. J. Cereb. Blood Flow Metab., 2003, 23, 531-535.
249. Braeuninger, S.; Kleinschnitz, C.; Stoll, G. Interleukin-18 does not influence infarct volume or functional outcome in the early stage after transient focal brain ischemia in mice. Exp. Transl. Stroke Med., 2010, 2, 1.
250. Zaremba, J.; Losy, J. Interleukin-18 in acute ischaemic stroke patients. Neurol. Sci., 2003, 24, 117-124.
251. Yuen, C.M.; Chiu, C.A.; Chang, L.T.; Liou, C.W.; Lu, C.H.; Youssef, A.A.; Yip, H.K. Level and value of interleukin-18 after acute ischemic stroke. Circ. J., 2007, 71, 1691-1696.
252. Jefferis, B.J.; Whincup, P.H.; Welsh, P.; Wannamethee, S.G.; Rumley, A.; Ebrahim, S.; Lawlor, D.A.; Lowe, G.D. Prospective study of IL-18 and risk of MI and stroke in men and women aged 60-79years: A nested case-control study. Cytokine, 2013, 61, 513-520.
253. Yang, L.; Zhang, Z.; Sun, D.; Xu, Z.; Zhang, X.; Li, L. The serum interleukin-18 is a potential marker for development of post-stroke depression. Neurol. Res., 2010, 32, 340-346.
254. Bossù, P.; Salani, F.; Cacciari, C.; Picchetto, L.; Cao, M.; Bizzoni, F.; Rasura, M.; Caltagirone, C.; Robinson, R.G.; Orzi, F.; Spalletta, G. Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. Curr. Neurovasc. Res., 2009, 6, 163-170.
255. Liu, T.; Clark, R.K.; McDonnell, P.C.; Young, P.R.; White, R.F.; Barone, F.C.; Feuerstein, G.Z. Tumor necrosis factor-alpha expression in ischemic neurons. Stroke, 1994, 25, 1481-1488.
256. Gregersen, R.; Lambertsen, K.; Finsen, B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab., 2000, 20, 53-65.
257. Dziewulska, D.; Mossakowski, M.J. Cellular expression of tumor necrosis factor a and its receptors in human ischemic stroke. Clin. Neuropathol., 2003, 22, 35-40.
258. Yin, L.; Ohtaki, H.; Nakamachi, T.; Dohi, K.; Iwai, Y.; Funahashi, H.; Makino, R.; Shioda, S. Expression of tumor necrosis factor alpha (TNFalpha) following transient cerebral ischemia. Acta Neurochir. Suppl., 2003, 86, 93-96.
259. Offner, H.; Subramanian, S.; Parker, S.M.; Afentoulis, M.E.; Vandenbark, A.A.; Hurn, P.D. Experimental stroke induces massive, rapid activation of the peripheral immune system. J. Cereb. Blood Flow Metab., 2006, 26, 654-665.
260. Tang, Y.; Shao, Y.; Su, J.; Zhou, H.; Liu, L.; Ren, H.; Dong, Q. The protein therapy of kallikrein in cerebral ischemic reperfusion injury. Curr. Med. Chem., 2009, 16, 4502-4510.
261. Nawashiro, H.; Martin, D.; Hallenbeck, J.M. Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J. Cereb. Blood Flow Metab., 1997, 17, 229-232.
262. Lavine, S.D.; Hofman, F.M.; Zlokovic, B.V. Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury. J. Cereb. Blood Flow Metab., 1998, 18, 52-58.
263. Yang, G.Y.; Gong, C.; Qin, Z.; Ye, W.; Mao, Y.; Bertz, A.L. Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport, 1998, 9, 2131-2134.
264. Bruce, A.J.; Boling, W.; Kindy, M.S.; Peschon, J.; Kraemer, P.J.; Carpenter, M.K.; Holtsberg, F.W.; Mattson, M.P. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat. Med., 1996, 2, 788794.
265. Gary, D.S.; Bruce-Keller, A.J.; Kindy, M.S.; Mattson, M.P. Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 tumor necrosis factor receptor. J. Cereb. Blood Flow Metab., 1998, 18, 1283-1287.
266. Taoufik, E.; Valable, S.; Muller, G.J.; Roberts, M.L.; Divoux, D.; Tinel, A.; Voulgari-Kokota, A.; Tseveleki, V.; Altruda, F.; Lassmann, H.; Petit, E.; Probert, L. FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J. Neurosci., 2007, 27, 6633-6646.
267. Lambertsen, K.L.; Clausen, B.H.; Babcock, A.A.; Gregersen, R.; Fenger, C.; Nielsen, H.H.; Haugaard, L.S.; Wirenfeldt, M.; Nielsen, M.; Dagnaes-Hansen, F.; Bluethmann, H.; Faergeman, N.J.; Meldgaard, M.; Deierborg, T.; Finsen, B. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J. Neurosci., 2009, 29, 1319-1330.
268. Pradillo, J,M.; Romera, C.; Hurtado, O.; Cárdenas, A.; Moro, M.A.; Leza, J.C.; Dávalos, A.; Castillo, J.; Lorenzo, P.; Lizasoain, I. TNFR1 upregulation mediates tolerance after brain ischemic preconditioning. J. Cereb. Blood Flow Metab., 2005, 25, 193-203.
269. Botchkina, G.I.; Meistrell, M.E. 3rd.; Botchkina, I.L.; Tracey, K.J. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol. Med., 1997, 3, 765-781.
270. Yin, L.; Ohtaki, H.; Nakamachi, T.; Kudo, Y.; Makino, R.; Shioda, S. Delayed expressed TNFR1 co-localize with ICAM-1 in astrocyte in mice brain after transient focal ischemia. Neurosci. Lett., 2004, 370, 30-35.
271. Lambertsen, K.L.; Clausen, B.H.; Fenger, C.; Wulf, H.; Owens, T.; Dagnaes-Hansen, F.; Meldgaard, M.; Finsen, B. Microglia and macrophages express tumor necrosis factor receptor p75 following middle cerebral artery occlusion in mice. Neuroscience, 2007, 144, 934-949.
272. Fontaine, V.; Mohand-Said, S.; Hanoteau, N.; Fuchs, C.; Pfizenmaier, K.; Eisel, U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J. Neurosci., 2002, 22, RC216.
273. Marchetti, L.; Klein, M.; Schlett, K.; Pfizenmaier, K.; Eisel, U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate- induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem., 2004, 279, 32869-32881.
274. Hallenbeck, J.M. The many faces of tumor necrosis factor in stroke. Nat. Med., 2002, 8, 1363-1368.
275. McCoy, M.K.; Tansey, M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation, 2008, 5, 45.
276. Gelderblom, M.; Weymar, A.; Bernreuther, C.; Velden, J.; Arunachalam, P.; Steinbach, K.; Orthey, E.; Arumugam, T.V.; Leypoldt, F.; Simova, O.; Thom, V.; Friese, M.A.; Prinz, I.; Hölscher, C.; Glatzel, M.; Korn, T.; Gerloff, C.; Tolosa, E.; Magnus, T. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood, 2012, 120, 3793-3802.
277. Konoeda, F.; Shichita, T.; Yoshida, H.; Sugiyama, Y.; Muto, G.; Hasegawa, E.; Morita, R.; Suzuki, N.; Yoshimura, A. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem. Biophys. Res. Commun., 2010, 402, 500-506.
278. Ma, S.; Zhong, D.; Chen, H.; Zheng, Y.; Sun, Y.; Luo, J.; Li, H.; Li, G.; Yin, Y. The immunomodulatory effect of bone marrow stromal cells (BMSCs) on interleukin (IL)-23/IL-17-mediated ischemic stroke in mice. J. Neuroimmunol., 2013, 257, 28-35.
279. Zeng, L.; Liu, J.; Wang, Y.; Wang, L.; Wenig, S.; Chen, S.; Yang, G.Y. Cocktail blood biomarkers: prediction of clinical outcomes in patients with acute ischemic stroke. Eur. Neurol., 2013, 69, 68-75.
280. Ali, C.; Nicole, O.; Docagne, F.; Lesne, S.; MacKenzie, E.T.; Nouvelot, A.; Buisson, A.; Vivien, D. Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain. J. Cereb. Blood Flow Metab., 2000, 20, 956-966.
281. Berti, R.; Williams, A.J.; Moffett, J.R.; Hale, S.L.; Velarde, L.C.; Elliott, P.J.; Yao, C.; Dave, J.R.; Tortella, F.C. Quantitative realtime RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J. Cereb. Blood Flow Metab., 2002, 22, 1068-1079.
282. Suzuki, S.; Tanaka, K.; Nogawa, S.; Nagata, E.; Ito, D.; Dembo, T.; Fukuuchi, Y. Temporal profile and cellular localization of interleukin- 6 protein after focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab., 1999, 19, 1256-1262.
283. Block, F.; Peters, M.; Nolden-Koch, M. Expression of IL-6 in the ischemic penumbra. Neuroreport, 2000, 11, 963-967.
284. Waje-Andreassen, U.; Kråkenes, J.; Ulvestad, E.; Thomassen, L.; Myhr, K.M.; Aarseth, J.; Vedeler, C.A. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol. Scand., 2005, 111, 360-365.
285. Beridze, M.; Sanikidze, T.; Shakarishvili, R.; Intskirveli, N.; Bornstein, N.M. Selected acute phase CSF factors in ischemic stroke: findings and prognostic value. BMC Neurol., 2011, 11, 41.
286. Emsley, H.C.; Smith, C.J.; Georgiou, R.F.; Vail, A.; Hopkins, S.J.; Rothwell, N.J.; Tyrrell, P.J.; Acute Stroke Investigators. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry, 2005, 76, 1366-1372.
287. Herrmann, O.; Tarabin, V.; Suzuki, S.; Attigah, N.; Coserea, I.; Schneider, A.; Vogel, J.; Prinz, S.; Schwab, S.; Monyer, H.; Brombacher, F.; Schwaninger, M. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J. Cereb. Blood Flow Metab., 2003, 23, 406-415.
288. Matsuda, S.; Wen, T.C.; Morita, F.; Otsuka, H.; Igase, K.; Yoshimura, H.; Sakanaka, M. Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils. Neurosci. Lett., 1996, 204, 109-112.
289. Loddick, S.A.; Turnbull, A.V.; Rothwell, N.J. Cerebral interleukin- 6 is neuroprotective during permanent focal cerebral ischemia in the rat. J. Cereb. Blood Flow Metab., 1998, 18, 176-179.
290. Yamashita, T.; Sawamoto, K.; Suzuki, S.; Suzuki, N.; Adachi, K.; Kawase, T.; Mihara, M.; Ohsugi, Y.; Abe, K.; Okano, H. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J. Neurochem., 2005, 94, 459-468.
291. Jung, J.E.; Kim, G.S.; Chan, P.H. Neuroprotection by interleukin-6 is mediated by signal transducer and activator of transcription 3 and antioxidative signaling in ischemic stroke. Stroke, 2011, 42, 3574-3579.
292. Sakata, H.; Narasimhan, P.; Niizuma, K.; Maier, C.M.; Wakai, T.; Chan, P.H. Interleukin 6-preconditioned neural stem cells reduce ischaemic injury in stroke mice. Brain, 2012, 135, 3298-3310.
293. Perini, F.; Morra, M.; Alecci, M.; Galloni, E.; Marchi, M.; Toso, V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol. Sci., 2001, 22, 289-296.
294. Vila, N.; Castillo, J.; Davalos, A.; Esteve, A.; Planas, A.M.; Chamorro, A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke, 2003, 34, 671-675.
295. Spera, P.; Ellison, J.;, Feuerstein, G.;, Barone, F. IL-10 reduces rat
296. Grilli, M.; Barbieri, I.; Basudev, H.; Brusa, R.; Casati, C.; Lozza, G.; Ongini, E. Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur. J. Neurosci., 2000, 12, 2265-2272.
297. Morita, Y.; Takizawa, S.; Kamiguchi, H.; Uesugi, T.; Kawada, H.; Takagi, S. Administration of hematopoietic cytokines increases the expression of anti-inflammatory cytokine (IL-10) mRNA in the subacute phase after stroke. Neurosci. Res., 2007, 58, 356-360.
298. Yan, J.; Greer, J.M.; McCombe, P.A. Prolonged elevation of cytokine levels after human acute ischaemic stroke with evidence of individual variability. J. Neuroimmunol., 2012, 246, 78-84.
299. Lehrmann, E.; Kiefer, R.; Christensen, T.; Toyka, K.V.; Zimmer, J.; Diemer, N.H.; Hartung, H.P.; Finsen, B. Microglia and macrophages are major sources of locally produced transforming growth factor-beta1 after transient middle cerebral artery occlusion in rats. Glia, 1998, 24, 437-448.
300. Yamashita, K.; Gerken, U.; Vogel, P.; Hossmann, K.; Wiessner, C. Biphasic expression of TGF-beta1 mRNA in the rat brain following permanent occlusion of the middle cerebral artery. Brain Res., 1999, 836, 139-145.
301. Ali, C.; Docagne, F.; Nicole, O.; Lesné, S.; Toutain, J.; Young, A.; Chazalviel, L.; Divoux, D.; Caly, M.; Cabal, P.; Derlon, J.M.; MacKenzie, E.T.; Buisson, A.; Vivien, D. Increased expression of transforming growth factor-beta after cerebral ischemia in the baboon: an endogenous marker of neuronal stress? J. Cereb. Blood Flow Metab., 2001, 21, 820-827.
302. Doyle, K.P.; Cekanaviciute, E.; Mamer, L.E.; Buckwalter, M.S. TGF signaling in the brain increases with aging and signals to astrocytes and innate immune cells in the weeks after stroke. J. Neuroinflammation, 2010, 7, 62.
303. Ruocco, A.; Nicole, O.; Docagne, F.; Ali, C.; Chazalviel, L.; Komesli, S.; Yablonsky, F.; Roussel, S.; MacKenzie, E.T.; Vivien, D.; Buisson, A. A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J. Cereb. Blood Flow Metab., 1999, 19, 1345-1353.
304. Pang, L.; Ye, W.; Che, X.M.; Roessler, B.J.; Betz, A.L.; Yang, G.Y. Reduction of inflammatory response in the mouse brain with adenoviral-mediated transforming growth factor-1 expression. Stroke, 2001, 32, 544-552.
305. Logan, A.; Berry, M.; Gonzalez, A.M.; Frautschy, S.A.; Sporn, M.B.; Baird, A. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur. J. Neurosci., 1994, 6, 355-363.
306. Zhu, Y.; Yang, G.Y.; Ahlemeyer, B.; Pang, L.; Che, X.M.; Culmsee, C.; Klumpp, S.; Krieglstein, J. Transforming growth factorbeta 1 increases bad phosphorylation and protects neurons against damage. J. Neurosci., 2002, 22, 3898-3909.
307. Ma, M.; Ma, Y.; Yi, X.; Guo, R.; Zhu, W.; Fan, X.; Xu, G.; Frey, W.H. 2nd; Liu, X. Intranasal delivery of transforming growth factorbeta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci., 2008, 9, 117.
308. Wang, X.; Yue, T.L.; Barone, F.C.; Feuerstein, G.Z. Monocyte chemoattractant protein-1 messenger RNA expression in rat ischemic cortex. Stroke, 1995, 26, 661-665.
309. Che, X.; Ye, W.; Panga, L.; Wu, D.C.; Yang, G.Y. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res., 2001, 902, 171-177.
310. Takami, S.; Minami, M.; Nagata, I.; Namura, S.; Satoh, M. Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab., 2001, 21, 1430-1435.
311. Minami, M.; Satoh, M. Chemokines and their receptors in the brain: pathophysiological roles in ischemic brain injury. Life Sci., 2003, 74, 321-327.
312. Losy, J.; Zaremba, J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke, 2001, 32, 2695-2696.
313. Hughes, P.M.; Allegrini, P.R.; Rudin, M.; Perry, V.H.; Mir, A.K.; Wiessner, C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow Metab., 2002, 22, 308-317.
314. Dimitrijevic, O.B.; Stamatovic, S.M.; Keep, R.F.; Andjelkovic, A.V. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke, 2007, 38, 1345-1353.
315. Schilling, M.; Strecker, J.K.; Ringelstein, E.B.; Schäbitz, W.R.; Kiefer, R. The role of CC chemokine receptor 2 on microglia activation and blood-borne cell recruitment after transient focal cerebral ischemia in mice. Brain Res., 2009, 1289, 79-84.
316. Strecker, J.K.; Minnerup, J.; Gess, B.; Ringelstein, E.B.; Schäbitz, W.R.; Schilling, M. Monocyte chemoattractant protein-1- deficiency impairs the expression of IL-6, IL-1 and G-CSF after transient focal ischemia in mice. PLoS One, 2011, 6, e25863.
317. Schuette-Nuetgen, K.; Strecker, J.K.; Minnerup, J.; Ringelstein, E.B.; Schilling, M. MCP-1/CCR-2-double-deficiency severely impairs the migration of hematogenous inflammatory cells following transient cerebral ischemia in mice. Exp. Neurol., 2012, 233, 849-858.
318. Chen, Y.; Hallenbeck, J.M.; Ruetzler, C.; Bol, D.; Thomas, K.; Berman, N.E.; Vogel, S.N. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab., 2003, 23, 748-755.
319. Robin, A.M.; Zhang, Z.G.; Wang, L.; Zhang, R.L.; Katakowski, M.; Zhang, L.; Wang, Y.; Zhang, C.; Chopp, M. Stromal cellderived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J. Cereb. Blood Flow Metab., 2006, 26, 125-134.
320. Yan, Y.P.; Sailor, K.A.; Lang, B.T.; Park, S.W.; Vemuganti, R.; Dempsey, R.J. Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J. Cereb. Blood Flow Metab., 2007, 27, 1213-1224.
321. Hill, W.D.; Hess, D.C.; Martin-Studdard, A.; Carothers, J.J.; Zheng, J.; Hale, D.; Maeda, M.; Fagan, S.C.; Carroll, J.E.; Conway, S.J. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J. Neuropathol. Exp. Neurol., 2004, 63, 84-96.
322. Kim, Y.S.; Baek, W.; Kim, M.K.; Kim, H.Y.; Lee, K.Y.; Lee, Y.J.; Kim, S.H.; Chang, D.I.; Koh, S.H. Association between serum stromal cell-derived factor-1 and long-term outcome of acute ischemic stroke. Eur. Neurol., 2012, 67, 363-369.
323. Schutt, R.C.; Burdick, M.D.; Strieter, R.M.; Mehrad, B.; Keeley, E.C. Plasma CXCL12 levels as a predictor of future stroke. Stroke, 2012, 43, 3382-3386.
324. Cui, X.; Chen, J.; Zacharek, A.; Li, Y.; Roberts, C.; Kapke, A.; Savant-Bhonsale, S.; Chopp, M. Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke. Stem Cells, 2007, 25, 2777-2785.
325. Shyu, W.C.; Lin, S.Z.; Yen, P.S.; Su, C.Y.; Chen, D.C.; Wang, H.J.; Li, H. Stromal cell-derived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrowderived cells in stroke rats. J. Pharmacol. Exp. Ther., 2008, 324, 834-849.
326. Wang, Y.; Huang, J.; Li, Y.; Yang, G.Y. Roles of chemokine CXCL12 and its receptors in ischemic stroke. Curr. Drug Targets, 2012, 13, 166-172.
327. Huang, J.; Li, Y.; Tang, Y.; Tang, G.; Yang, G.Y.; Wang, Y. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke, 2013, 44, 190-197.
328. Lu, D.Y.; Tang, C.H.; Yeh, W.L.; Wong, K.L.; Lin, C.P.; Chen, Y.H.; Lai, C.H.; Chen, Y.F.; Leung, Y.M.; Fu, W.M. SDF-1alpha up-regulates interleukin-6 through CXCR4, PI3K/Akt, ERK, and NF-kappaB-dependent pathway in microglia. Eur. J. Pharmacol., 2009, 613, 146-154.
329. Lipfert, J.; Odemis, V.; Wagner, D.C.; Boltze, J.; Engele, J. CXCR4 and CXCR7 form a functional receptor unit for SDF- 1/CXCL12 in primary rodent microglia. Neuropathol. Appl. Neurobiol., 2013, 39, 667-680.
330. Chapman, G.A.; Moores, K.; Harrison, D.; Campbell, C.A.; Stewart, B.R.; Strijbos, P.J. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci., 2000, 20, RC87.
331. Tarozzo, G.; Campanella, M.; Ghiani, M.; Bulfone, A.; Beltramo, M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur. J. Neurosci., 2002, 15, 1663-1668.
332. Zhu, J.; Zhou, Z.; Liu, Y.; Zheng, J. Fractalkine and CX3CR1 are involved in the migration of intravenously grafted human bone marrow stromal cells toward ischemic brain lesion in rats. Brain Res., 2009, 1287, 173-183.
333. Soriano, S.G.; Amaravadi, L.S.; Wang, Y.F.; Zhou, H.; Yu, G.X.; Tonra, J.R.; Fairchild-Huntress, V.; Fang, Q.; Dunmore, J.H.; Huszar, D.; Pan, Y. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J. Neuroimmunol., 2002, 125, 59-65.
334. Cipriani, R.; Villa, P.; Chece, G.; Lauro, C.; Paladini, A.; Micotti, E.; Perego, C.; De Simoni, M.G.; Fredholm, B.B.; Eusebi, F.; Limatola, C. CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J. Neurosci., 2011, 31, 16327-16335.
335. Donohue, M.M.; Cain, K.; Zierath, D.; Shibata, D.; Tanzi, P.M.; Becker, K.J. Higher plasma fractalkine is associated with better 6- month outcome from ischemic stroke. Stroke, 2012, 43, 2300-2306.
336. Nogawa, S.; Zhang, F.; Ross, M.E.; Iadecola, C. Cyclo-oxygenase- 2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci., 1997, 17, 2746-2755.
337. Iadecola, C.; Forster, C.; Nogawa, S.; Clark, H.B.; Ross, M.E. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol., 1999, 98, 9-14.
338. Iadecola, C.; Niwa, K.; Nogawa, S.; Zhao, X.; Nagayama, M.; Araki, E.; Morham, S.; Ross, M.E. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. USA, 2001, 98, 1294-1299.
339. Bidmon, H.J.; Oermann, E.; Schiene, K.; Schmitt, M.; Kato, K.; Asayama, K.; Witte, O.W.; Zilles, K. Unilateral upregulation of cyclooxygenase- 2 following cerebral, cortical photothrombosis in the rat: suppression by MK-801 and co-distribution with enzymes involved in the oxidative stress cascade. J. Chem. Neuroanat., 2000, 20, 163-176.
340. Chakraborti, A.K.; Garg, S.K.; Kumar, R.; Motiwala, H.F.; Jadhavar, P.S. Progress in COX-2 inhibitors: a journey so far. Curr. Med. Chem., 2010, 17, 1563-1593.
341. Maguire, J.; Thakkinstian, A.; Levi, C.; Lincz, L.; Bisset, L.; Sturm, J.; Scott, R.; Whyte, S.; Attia, J. Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome: a novel finding. J. Stroke Cerebrovasc. Dis., 2011, 20, 134-144.
342. Candelario-Jalil, E.; González-Falcón, A.; García-Cabrera, M.; León, O.S.; Fiebich, B.L. Post-ischaemic treatment with the cyclooxygenase- 2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J. Neurochem., 2007, 100, 1108-1120.
343. Kawano, T.; Anrather, J.; Zhou, P.; Park, L.; Wang, G.; Frys, K.A.; Kunz, A.; Cho, S.; Orio, M.; Iadecola, C. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat. Med., 2006, 12, 225-229.
344. Forster, C.; Clark, H.B.; Ross, M.E.; Iadecola, C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol., 1999, 97, 215-220.
345. Nakashima, M.N.; Yamashita, K.; Kataoka, Y.; Yamashita, Y.S.; Niwa, M. Time course of nitric oxide synthase activity in neuronal, glial, and endothelial cells of rat striatum following focal cerebral ischemia. Cell. Mol. Neurobiol., 1995, 15, 341-349.
346. Iadecola, C.; Zhang, F.; Casey, R.; Clark, H.B.; Ross, M.E. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke, 1996, 27, 1373-1380.
347. Iadecola, C.; Zhang, F.; Casey, R.; Nagayama, M.; Ross, M.E. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J. Neurosci., 1997, 17, 9157-9164.
348. Moro, M.A.; Cárdenas, A.; Hurtado, O.; Leza, J.C.; Lizasoain, I. Role of nitric oxide after brain ischaemia. Cell Calcium, 2004, 36, 265-275.
349. Murphy, S.; Gibson, C.L. Nitric oxide, ischaemia and brain inflammation. Biochem. Soc. Trans., 2007, 35, 1133-1137.
350. Kanwar, J.R.; Kanwar, R.K.; Burrow, H.; Baratchi, S. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr. Med. Chem., 2009, 16, 2373-2394.
351. Peng, B.; Guo, Q.L.; He, Z.J.; Ye, Z.; Yuan, Y.J.; Wang, N.; Zhou, J. Remote ischemic postconditioning protects the brain from global cerebral ischemia/reperfusion injury by up-regulating endothelial nitric oxide synthase through the PI3K/Akt pathway. Brain Res., 2012, 1445, 92-102.
352. Pignataro, G.; Esposito, E.; Sirabella, R.; Vinciguerra, A.; Cuomo, O.; Di Renzo, G.; Annunziato, L. nNOS and p-ERK involvement in the neuroprotection exerted by remote postconditioning in rats subjected to transient middle cerebral artery occlusion. Neurobiol. Dis., 2013, 54, 105-114.
353. Nogawa, S.; Forster, C.; Zhang, F.; Nagayama, M.; Ross, M.E.; Iadecola, C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc. Natl. Acad. Sci. USA, 1998, 95, 10966-10971.
354. Greco, R.; Mangione, A.S.; Amantea, D.; Bagetta, G.; Nappi, G.; Tassorelli, C. IkappaB-alpha expression following transient focal cerebral ischemia is modulated by nitric oxide. Brain Res., 2011, 1372, 145-151.
355. Yu, H.M.; Xu, J.; Li, C.; Zhou, C.; Zhang, F.; Han, D.; Zhang, G.Y. Coupling between neuronal nitric oxide synthase and glutamate receptor 6-mediated c-Jun N-terminal kinase signaling pathway via S-nitrosylation contributes to ischemia neuronal death. Neuroscience, 2008, 155, 1120-1132.
356. Gu, Z.; Kaul, M.; Yan, B.; Kriedel, S.J.; Cul, J.; Strongin, A.; Smith, J.W.; Liddington, R.C.; Lipton, S.A. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science, 2002, 297, 1186-1190.
357. Sternlicht, M.D.; Werb, Z. How matrix metalloproteinases regulate cell behaviour. Annu. Rev. Cell Dev. Biol., 2001, 17, 463-516.
358. Hadler-Olsen, E.; Fadnes, B.; Sylte, I.; Uhlin-Hansen, L.; Winberg, J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J., 2011, 278, 28-45.
359. Rosenberg, G.A. Matrix metalloproteinases in neuroinflammation. Glia, 2002, 39, 279-291.
360. Cunningham, L.A.; Wetzel, M.; Rosenberg, G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia, 2005, 50, 329-339.
361. Romanic, A.M.; White, R.F.; Arleth, A.J.; Ohlstein, E.H.; Barone, F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke, 1998, 29, 1020-1030.
362. Heo, J.H.; Lucero, J.; Abumiya, T.; Koziol, J.A.; Copeland, B.R.; del Zoppo, G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J. Cereb. Blood Flow Metab., 1999, 19, 624-633.
363. Asahi, M.; Asahi, K.; Jung, J.C.; del Zoppo, G.J.; Fini, M.E.; Lo, E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockdown and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab., 2000, 20, 1681-1689.
364. Horstmann, S.; Kalb, P.; Koziol, J.; Gardner, H.; Wagner, S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke, 2003, 34, 2165-2170.
365. Rosell, A.; Ortega-Aznar, A.; Alvarez-Sabin, J.; Fernandez- Cadenas, I.; Ribo, M.; Molina, C.A.; Lo, E.H.; Montanter, J. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke, 2006, 37, 1399-1406.
366. Rosell, A.; Cuadrado, E.; Ortega-Aznar, A.; Hernández-Guillamon, M.; Lo, E.H.; Montaner, J. MMP-9-Positive Neutrophil Infiltration Is Associated to Blood-Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke. Stroke, 2008, 39, 1121-1126.
367. Ulrich, N.H.; Dehmel, T.; Wittsack, H.J.; Kieseier, B.C.; Seitz, R.J. Peripheral blood levels of matrix metalloproteinase-9 predict lesion volume in acute stroke. Neurol. Sci. 2013, 34, 379-382.
368. Rodríguez-Yáñez, M.; Sobrino, T.; Arias, S.; Vázquez-Herrero, F.; Brea, D.; Blanco, M.; Leira, R.; Castellanos, M.; Serena, J.; Vivancos, J.; Dávalos, A.; Castillo, J. Early biomarkers of clinicaldiffusion mismatch in acute ischemic stroke. Stroke, 2011, 42, 2813-2818.
369. Planas, A.M.; Sole, S.; Justicia, C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol. Dis, 2001, 8, 834-846.
370. Rosenberg, G.A.; Cunningham, L.A.; Wallace, J.; Alexander, S.; Estrada, E.Y.; Grossetete, M.; Razhagi, A.; Miller, K.; Gearing, A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury in rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res., 2001, 893, 104-112.
371. Gu, Z.; Cui, J.; Brown, S.; Fridman, R.; Mobashery, S.; Strongin, A.Y.; Lipton, S.A. A highly specific inhibitor of matrix metalloproteinase- 9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci., 2005, 25, 6401-6408.
372. Yang, Y.; Estrada, E.Y.; Thompson, J.F.; Liu, W.; Rosenberg, G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab., 2007, 27, 697-709.
373. Amantea, D.; Corasaniti, M.T.; Mercuri, N.B.; Bernardi, G.; Bagetta, G. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience, 2008, 152, 8-17.
374. Hill, J.W.; Poddar, R.; Thompson, J.F.; Rosenberg, G.A.; Yang, Y. Intranuclear matrix metalloproteinases promote DNA damage and apoptosis induced by oxygen-glucose deprivation in neurons. Neuroscience, 2012, 220, 277-290.
375. Gasche, Y.; Copin, J.C.; Sugawara, T.; Fujimura, M.; Chan, P.H. Matrix metalloproteinase inhibition prevents oxidative stress associated blood-brain barrier disruption after transient focal cerebral ischemia. J. Cereb. Blood Flow Metab., 2001, 21, 1393-1400.
376. Asahi, M.; Sumii, T.; Fini, M.E.; Itohara, S.; Lo E.H. Matrix metalloproteinase- 2 gene knock out has no effect on acute brain injury after focal ischemia. NeuroReport, 2001, 17, 3003-3007.
377. Asahi, M.; Wang, X.; Mori, T.; Sumii, T.; Jung, J.C.; Moskowitz, M.A.; Fini, M.E.; Lo, E.H. Effects of matrix metalloproteinase 9 gene knock out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J. Neurosci., 2001, 21, 7724-7732.
378. Wang, X.; Jung, J.C.; Asahi, M.; Chwang, W.; Russo, L.; Moskowitz, M.A.; Dixon, C.E.; Fini, E.; Lo, E.H. Effects of matrix metalloproteinase 9 gene knock out on morphological and motor outcomes after traumatic brain injury. J. Neurosci., 2000, 20, 7037-7042.
379. Jourquin, J.; Tremblay, E.; Decanis, N.; Charton, G.; Hanessian, S.; Chollet, A.M.; Le Diguardher, T.; Khrestchatiski, M.; Rivera, S. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur. J. Neurosci., 2003, 18, 1507-1517.
380. Copin, J.C.; Goodyear, M.C.; Gidday, J.M.; Shah, A.R.; Gascon, E.; Dayer, A.; Morel, D.M.; Gasche, Y. Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur. J. Neurosci., 2005, 22, 1597-1608.
381. Wetzel, M.; Rosenberg, G.A.; Cunningham, L.A. Tissue inhibitor of metalloproteinase-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis. Eur. J. Neurosci., 2003, 18, 1050-1060.
382. Lee, R.; Kermani, P.; Teng, K.K.; Hempstead, B.L. Regulation of cell survival by secreted proneurotrophins. Science, 2001, 94, 1945-1948.
383. Zhang, K.; McQuibban, G.A.; Silva, C.; Butler, G.S.; Johnston, J.B.; Holden, J.; Clark-Lewis, I.; Overall, C.M.; Power, C. HIVinduced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat. Neurosci., 2003, 6, 1064-1071.
384. Zhu, W.; Khachi, S.; Hao, Q.; Shen, F.; Young, W.L.; Yang, G.Y.; Chen, Y. Upregulation of EMMPRIN after permanent focal cerebral ischemia. Neurochem. Int., 2008, 52, 1086-1091.
385. Zhao, B.Q.; Wang, S.; Kim, H.Y.; Storrie, H.; Rosen, B.R.; Mooney, D.J.; Wang, X.; Lo, E.H. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat. Med., 2006, 12, 441-445.
386. Yang, Y.; Rosenberg, G.A. MMP-mediated disruption of claudin-5 in the blood-brain barrier of rat brain after cerebral ischemia. Methods Mol. Biol., 2011, 762, 333-345.
387. Liu, J.; Jin, X.; Liu, K.J.; Liu, W. Matrix metalloproteinase-2- mediated occluding degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage. J. Neurosci., 2012, 32, 3044-57.
388. Lampl, Y.; Boaz, M.; Gilad, R.; Lorberboym, M.; Dabby, R.; Rapoport, A.; Anca-Hershkowitz, M.; Sadeh, M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology., 2007, 69, 1404-1410.
389. Fagan, S.C.; Waller, J.L.; Nichols, F.T.; Edwards, D.J.; Pettigrew, L.C.; Clark, W.M.; Hall, C.E.; Switzer, J.A.; Ergul, A.; Hess, D.C. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke., 2010, 41, 2283-2287.
390. Pettigrew, L.C.; Kasner, S.E.; Albers, G.W.; Gorman, M.; Grotta, J.C.; Sherman, D.G. Funakoshi Y, Ishibashi H; Arundic Acid (ONO-2506) Stroke Study Group. Safety and tolerability of arundic acid in acute ischemic stroke. J. Neurol. Sci., 2006, 251, 50-56.
391. Ishibashi, H.; Pettigrew, L.C.; Funakoshi, Y.; Hiramatsu, M. Pharmacokinetics of arundic acid, an astrocyte modulating agent, in acute ischemic stroke. J. Clin. Pharmacol., 2007, 47, 445-452.
392. Veldhuis, W.B.; Derksen, J.W.; Floris, S.; Van Der Meide, P.H.; De Vries, H.E.; Schepers, J.; Vos, I.M.; Dijkstra, C.D.; Kappelle, L.J.; Nicolay, K.; Bär, P.R. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J. Cereb. Blood Flow Metab., 2003, 23, 1029-1039.
393. Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology, 2001, 57, 1428-1434.
394. Becker K.J. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr. Med. Res. Opin., 2002, 18, 18-22.
395. Krams, M.; Lees, K.R.; Hacke, W.; Grieve, A.P.; Orgogozo, J.M.; Ford, G.A. ASTIN Study Investigators. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose response study of UK-279,276 in acute ischemic stroke. Stroke, 2003, 34, 2543-2548.
396. Sughrue, M.E.; Connolly, E.S. Jr. Effectively bridging the preclinical/ clinical gap: the results of the ASTIN trial. Stroke, 2004, 35, e81-82.
397. Takeda, H.; Spatz, M.; Ruetzler, C.; McCarron, R.; Becker, K.; Hallenbeck, J. Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke-prone rats. Stroke, 2002, 33, 2156-2163.
398. Basta, M.; Kirshbom, P.; Frank, M.M.; Fries, L.F. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest., 1989, 84, 1974-1981.
399. Arumugam, T.V.; Tang, S.C.; Lathia, J.D.; Cheng, A.; Mughal, M.R.; Chigurupati, S.; Magnus, T.; Chan, S.L.; Jo, D.G.; Ouyang, X.; Fairlie, D.P.; Granger, D.N.; Vortmeyer, A.; Basta, M.; Mattson, M.P. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complementmediated neuronal cell death. Proc. Natl. Acad. Sci. U S A, 2007, 104, 14104-14109.
400. Walberer, M.; Nedelmann, M.; Ritschel, N.; Mueller, C.; Tschernatsch, M.; Stolz, E.; Bachmann, G.; Blaes, F.; Gerriets, T. Intravenous immunoglobulin reduces infarct volume but not edema formation in acute stroke. Neuroimmunomodulation, 2010, 17, 97-102.